La FDA está imponiendo nuevas advertencias sobre los populares medicamentos para bajar de peso debido a una posible relación con una rara condición ocular que puede causar pérdida permanente de visión.
Resumen generado con IA. Consulta el original para comprobar el contexto y la precisión.
Este es el extracto disponible del feed. Puede estar abreviado o en el idioma original.
The Food and Drug Administration is warning that popular obesity drugs—including Ozempic, Wegovy, Zepbound, and Mounjaro—may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss. In a drug safety communication Monday, the FDA said it will now require makers of GLP-1 receptor agonist drugs to add a warning about that risk on their drug labels. The specific eye condition it warns of is called non-arteritic anterior ischemic optic neuropathy or NAION. The condition is caused by restricted blood flow to the optic nerve, which leads to swelling and cell death and ultimately damages the nerve, causing abrupt vision loss that can often be permanent. It's unknown how GLP-1 drugs may cause NAION. The condition is rare overall, occurring in somewhere between two and 10 people in 100,000 in the general population, according to the American Academy of Ophthalmologists. These small numbers have made it more difficult to determine with certainty if there is a connection. Further complicating the potential link is the fact that the risk factors for developing NAION are common among patients taking GLP-1 drugs. The risk factors include diabetes, cardiovascular disease, high blood pressure, high cholesterol, metabolic syndrome, and obstructive sleep apnea.Read full article Comments
Una ayuda automática para ordenar, basada en fuentes, palabras clave y entidades, en una escala de 1–12. Alta: 9–12; media: 6–8; baja: 1–5. No mide urgencia, verifica noticias ni representa respaldo editorial.
La traducción se está preparando.
La traducción se está preparando.
La traducción se está preparando.